Sunday, May 5, 2013

NFL Players Union Rebukes Teams For Asking Players If They ‘Like Girls’

Colorado's Nick Kasa

If National Football League teams are asking prospective players about their sexuality, that would be a violation of the law and the league’s collective bargaining agreement, the NFL Players’ Association said Wednesday. Pro Football Talk’s Mike Florio reported this week that teams wanted to know if Notre Dame linebacker Manti Te’o is gay, after the projected first-round pick was embroiled involving a fake girlfriend this winter. A second player, University of Colorado tight end Nick Kasa, said today that NFL teams had asked questions about his sexuality.

Kasa, who is projected to be selected in April’s draft, told an ESPN Radio affiliate in Denver that teams have asked him whether he has a girlfriend and if he likes girls, Queerty noted:

“[Teams] ask you, like, ‘Do you have a girlfriend?’ Are you married? Do you like girls?’ Those kinds of things, and you know it was just kind of weird. But they would ask you with a straight face, and it’s a pretty weird experience altogether.”

Such questions from NFL teams would be a violation of the league’s collective bargaining agreement, which includes a non-discrimination clause that covers sexual orientation. In a statement emailed to ThinkProgress, NFL Players Association executive director DeMaurice Smith said the league should “seek out information” about which teams have asked questions about sexuality:

“I know that the NFL agrees that these types of questions violate the law, our CBA and player rights. I hope that they will seek out information as to what teams have engaged in this type of discrimination, and we should then discuss appropriate discipline.”

The non-discrimination provision was added to the collective bargaining agreement during labor negotiations in 2011. It covers all current and prospective NFL employees.

The NFL will investigate the line of questioning, it said in a statement to CBS Sports. “Like all employers, our teams are expected to follow applicable federal, state and local employment laws,” the NFL said in a statement. “It is league policy to neither consider nor inquire about sexual orientation in the hiring process. In addition, there are specific protections in our collective bargaining agreement with the players that prohibit discrimination against any player, including on the basis of sexual orientation. We will look into the report on the questioning of Nick Kasa at the Scouting Combine. Any team or employee that inquires about impermissible subjects or makes an employment decision based on such factors is subject to league discipline.”


View the original article here

India panel proposes to regulate prices of patented medicines

By Kaustubh Kulkarni

MUMBAI, Feb 26 (Reuters) - An Indian government panel has proposed that prices of patented medicines be based on the country's per capita income, a move that would substantially reduce prices of costly drugs made by global pharmaceutical firms.

The proposal, which seeks the input of other government agencies as well as industry groups, could provoke the ire of Big Pharma, which has clashed with India over protection of intellectual property, price regulations for generic drugs, and compulsory licenses for costly medicines.

A panel formed under the ministry of chemicals and fertilizers has recommended setting up a committee to negotiate with drugmakers to fix prices of costly drugs used to treat deadly diseases such as cancer, HIV and hepatitis.

The proposal is the latest in a series of measures taken by India to make medicines more affordable for the country's 1.2 billion population.

"If we compare the per-capita income with the prices of patented medicines in countries like Australia or France, prices in India are comparatively high and hence, they need to be regulated," a senior ministry official told Reuters, declining to be identified because he was not authorised to speak with media.

Generic medicines account for more than 90 percent of India's $13 billion pharmaceuticals market. U.S.-based Abbott Laboratories has the largest share of the overall Indian drug market followed by India's Cipla .

The proposal, posted late on Monday on the ministry website, cites as an example the lung-cancer drug erlotinib HCL, sold by Roche Holding AG as Tarceva. In India, it costs 35,450 rupees ($660) for one month of 100 mg tablets, equivalent to 121,085 rupees in France and 121,650 rupees in Australia.

Based on per-capita gross national incomes, if the drug costs 35,450 rupees in India, its respective cost would be just 11,643 rupees in France and 10,309 rupees in Australia based on per capita income in the respective countries, the report said.

The Organization of Pharmaceutical Producers of India, which represents foreign drugmakers in India, did not reply to questions from Reuters.

"If stringent price regulations are enforced then latest drugs will not be made available in India," said Ameet Hariani, managing partner at Hariani & Co, a Mumbai-based law firm that advises drugmakers and other companies.

($1 = 53.89 rupees)

(Editing by Tony Munroe and Louise Heavens)

((kaustubh.kulkarni@thomsonreuters.com)(+91 22 61807399)(Reuters Messaging: kaustubh.kulkarni.thomsonreuters.com@reuters.net))

Keywords: INDIA PHARMA/PRICES


View the original article here

GOP Senators: We’ll Hold Up Treasury Nominee Unless Obama Makes Medicare Cuts That He’s Already Made

In a letter sent to the White House on Tuesday, 22 Republican senators are demanding that President Obama propose Medicare cuts before the chamber considers Treasury Secretary nominee Jack Lew.

The letter is part of an ongoing GOP smear campaign against Lew alleging that, during his tenure as director of the Office of Management and Budget (OMB), Lew and the Obama Administration failed to comply with a law requiring the White House to submit Medicare cost-cutting proposals “whenever the program’s trustees express concerns about its solvency in their annual report.” The senators suggest that Lew should have known about that legal requirement and spurred the Administration to take action by formally proposing Medicare cuts:

“We find it stunning and noteworthy that so far Mr. Lew has not provided adequate responses to congressional inquiries on the matter,” the senators wrote to Obama Tuesday.

“Congress needs a clearer understanding about his role in the violation of this law, including exactly when Mr. Lew first became aware of this legal requirement and what counsel, if any, he provided the administration on whether it should comply with this law.”

But there are some glaring falsehoods in the senators’ claims and their subsequent demand for an Administration plan to curb Medicare cost growth.

First, calling for Medicare cuts to ensure the program’s long-term solvency is based on the assumption that inflation in medical services — and, consequently, spending on health care entitlements like Medicare — will continue to balloon at staggering rates indefinitely. But the key to reducing national health expenditures is to reduce the actual price of consuming care — so if forces in the health care market facilitate cost reductions in medical technology and services, then entitlement spending will drop accordingly. Recent evidence shows that that is exactly what is happening, as the recent slowdown in health care cost growth has reduced Medicare’s future projected spending by over half a trillion dollars, all without a single policy change. Furthermore, a just-released GAO report found that if Obamacare and its cost-containment mechanisms are fully implemented, then future spending on Medicare would decrease “from 6.2 percent of GDP in 2035 in the simulations run before [Obamacare] was enacted to 4.7 percent in the simulations run immediately after enactment.”

President Obama also directly cut Medicare spending to the tune of $716 billion over the next decade by signing Obamacare, which reduces overpayments to providers servicing private Medicare Advantage plans. In fact, the GOP — led by their presidential nominee, Mitt Romney — hammered the president mercilessly over these cuts during the 2012 election cycle, claiming that the provider payment reductions amounted to “robbing Medicare.” And the president has proposed further cuts to entitlement programs — including Medicare — on multiple occasions, including his proposed budget and this month’s State of the Union address.

The only way that the senators’ claims bear credence is if they are hewing to an absurdly narrow, literal interpretation of the law in question, and want the Administration to submit a single specific bill addressing Medicare cuts. But the more likely explanation is that the senators are engaging in a bit of political grandstanding that affords them an opportunity to attack both the president’s entitlement policies as well as one of his highest-profile cabinet nominees.


View the original article here

UPDATE 1-Royalty Pharma plans to tap Elan investors on offer -source

* Royalty has not received response from Elan

* Biggest shareholder is Johnson & Johnson

(Adds Royalty Pharma declined to comment, updates share price, analyst comment)

By Jessica Toonkel

NEW YORK, Feb 26 (Reuters) - New York-based investment firm Royalty Pharma does not want to take "no" for an answer to its $6.6 billion offer for Irish drugmaker Elan Corp .

The company plans to spend the next few weeks calling Elan shareholders about its offer made on Feb. 18, according to a source familiar with the situation.

Royalty Pharma, which buys royalty streams of patented drugs and whose portfolio includes rheumatoid arthritis treatments Humira and Remicade, is turning to Elan's investors because it has received no formal response from the company about its offer, said the source, who wished to remain anonymous because of not being allowed to speak to the media.

Elan's biggest shareholder is Johnson & Johnson with an 18 percent stake.

An Elan spokesman declined to comment, as did Johnson & Johnson. A Royalty Pharma spokesman did not return a request for comment.

Royalty Pharma's offer, worth $11 per Elan share, came just days after Elan announced it had sold its 50 percent interest in multiple sclerosis drug Tysabri for $3.25 billion plus future royalty payments to U.S. partner Biogen Idec.

As a result of the Tysabri sale, Elan announced on Friday that it would return $1 billion to shareholders and make acquisitions with the rest of the $3.25 billion raised from the deal. Elan did not disclose the Royalty Pharma offer, which was not a formal bid.

Elan, in a statement on Monday, said Royalty Pharma's bid was an "indicative, conditional, proposal which may or may not lead to an offer being made for the entire issued share capital of the Company".

Elan also called the Royalty Pharma bid "highly opportunistic", given that shareholders had not had the opportunity to assess the full benefits of the Tysabri sale.

However, Royalty Pharma does not think Elan's management had the experience to make acquisitions, the firm said in its statement announcing its proposed offer on Monday.

Still, Royalty Pharma may have a tough time buying Elan given its $11-a-share offer, wrote Corey Davis, an equity analyst for Jefferies, in a note on Tuesday.

Royalty Pharma will have to get closer to $20 a share if it wants to buy the company, wrote Davis, who has a "buy" on Elan.

Elan's stock on Tuesday closed slightly above the offer price at $11.03, a 7 percent increase from Friday's close on the New York Stock Exchange.

(Reporting By Jessica Toonkel; Editing by Maureen Bavdek and Dale Hudson)

((Jessica.toonkel@thomsonreuters.com)(646-223-7882)(Twitter:

@jtoonkel)(Reuters Messaging: jessica.toonkel@thomsonreuters.com))

Keywords: ROYALTYPHARMA ENDO/


View the original article here

DAY'S END ROUNDUP

FROM THE BLOGS:

Bob Woodward demands law-ignoring, mind-controlling presidential leadership
Salon.com's Alex Pareene says a Washington Post reporter's comments about President Obama's involvement in the sequester battle are unfounded.

The economic closet: the business case for gay marriage

The New Yorker's Amy Davidson argues that legalizing gay marriage can be good for businesses and the economy.

Christie shrugs off CPAC snub

Ed Krayewski writes at Reason's Hit and Run Blog about CPAC's shunning of the popular New Jersey Governor.

Hagel supporters suddenly singing different tune
Commentary's Seth Mandel thinks that original supporters of Defense Secretary Chuck Hagel are coming to the realization that his critics were right.

OTHER NEWS SOURCES:

Obama to meet with leaders on sequester the day cuts take effect
The Hill's Amie Parnes reports on the President's scheduled meeting with lawmakers in order to prevent dramatic cuts from going into effect.

Rubio urges administration to provide aid to Syrian opposition

Sen. Marco Rubio (R-Fla.) is suggesting sending ammunition and body armor to Syrian opposition forces, according to The Hill's Julian Pecquet.

View Comments

View the original article here

Kerry goes to Ankara

Before Secretary of State John Kerry arrives in Turkey on March 1, he would better reconsider the trajectory of relations with Turkey. Kerry is known to value the Transatlantic ties and is keen on an active U.S. role in Turkey’s broader neighborhood. But he needs to contextualize his case against the current misfit between the two countries’ foreign policy agendas.

The Obama administration has developed an unprecedented level of consultation with Erdogan and his government. The Turkish leadership was particularly hopeful about Obama’s second term, envisioning possibly a free reign to overcome traditional U.S. prejudices in regional diplomacy and more importantly an enforced commitment to ending the bloodshed in Syria and, hopefully, a move to resolve the Iranian nuclear issue. In Washington, Turkey’s realignment with the U.S. particularly after the employment of the missile radar system and Ankara’s decision to side with the Syrian opposition despite Iranian and Russian objections appeared as good news. Today, with Patriot missiles situated in Turkey and unwavering U.S. support for Turkish
defenses, the security cooperation is at a historical height. Yet, this semblance of increased convergence in relations might prove insufficient to hide the underlying divergences in both countries diplomatic agendas.

Issues at stake

Syria has been a manageable disappointment for the Turkish leadership so far, given how promising things appeared in the very beginning when all castles seemed to be falling before the tide of Turkish influence in the region. The Turkish expectation was to swiftly have Assad replaced, who turned himself into a liability against the Turkish plan to transform the region into a zone of economic integration and multicultural coexistence. The Turkish tone was not sectarian, rather populist that aimed at warranting ties with the post-Assad Syria. Yet, Turkey found itself in the midst of regional power rivalries and even worse with an aloof U.S. and, unsurprisingly, disinterested EU who were supposed to be the advocates of democratic aspirations in the region. At the end of the day, not only an early possibility of democratic transition has been lost, but also hopes for a peaceful one were dashed by inaction. Secretary Kerry reportedly advocates an enforced U.S. role. This view will likely be reinforced after meetings in Ankara and subsequent regional capitals of the tour. Yet, the biggest challenge before active engagement is the Obama Administration’s reservations about another “adventure” overseas that would sidetrack the ultimate objective of internal restructuring.

Iraq for different reasons also burdens the relationship. Ankara-Baghdad relations turned sour after Maliki paradoxically perceived the Turkish position to promote consensual politics not only in Iraq, but also in Syria as threatening. At home he shied away from power sharing, abroad he feared yet another Sunni ascendancy. The resultant equation is the U.S.-encouraged Maliki coalesces with Iran and the Baathist Assad. Turkey sided with the KRG and Sunni minority against an “oppressing” Maliki majority bloc, yet acted reservedly not to alienate other Shiite groups. Iran’s policy has been to aggravate
Shiite-Sunnite tensions in Iraq and the region to hedge against its political losses after the Arab Spring. Meanwhile, Turkey’s burgeoning energy and security needs entailed a rapprochement with the KRG, which was earlier advocated by the Americans but went even further than U.S. projections. Overall, for Ankara, the U.S. siding with Maliki in the name of political stability is a faux pas that requires reparation. This is while the U.S. came out vocal in opposing Turkish-KRG cooperation particularly on energy. Maliki’s ties with Ankara seem irreparable and until US pretension about political stability in Iraq ends both sides will continue to differ on Iraqi affairs.

Turkish-Israeli relations were suspended but luckily did not deteriorate. The U.S. after a few attempts decided to step aside not to overload an already difficult reconciliation process. The controversy actually cooled down and thanks to both sides’ maturity did not evolve into a structural disconnect. Under current terms, the ground is ripe for a new rapprochement unless the process is politicized by respective domestic audiences.

Such a reconciliation, however, would even further isolate Iran. Tehran chose to stand against a rising Turkish influence in Syria, risking any remaining hope for connecting with the Arab street. Their calculation was to offset Turkey’s empowered ties with Egypt, Tunisia and Libya by a Shiite front stretching from Lebanon to Syria and Iraq. Turkey’s impaired ties with Tel Aviv were in itself an asset for Iran in this power equation. With renewed efforts for reconciliation, Israel’s concern for a rising Islamic tide in the region can be mitigated in consultation with Turkey, who in turn can bridge the gap between Israel and the Islamists.

Yet, the U.S. should not misread the new regional dynamics to expect Turkey and Iran openly confront each other. A war of attrition between two has historically been discredited. And under current circumstances both sides will limit their tactical moves once that touches sensitive territory. That sensitive territory is any intervention in their respective domestic issues. In Iran national political arena has never restored the self-confidence it enjoyed before June 2009 and the incoming elections will be a critical attempt to reunite the embattled factions under the Supreme Leader’s authority. For Turkey, the ongoing reconciliatory talks with the Kurdish groups is also critical for lowering the heightened security risks after what has transpired in Syria.

On the bilateral menu, Kerry should be ready to face growing demands from the Turkish side for broadened economic cooperation. With President Obama’s “State of the Union” push for the Transatlantic Trade and Investment Partnership (TTIP), Ankara will feel the heat hereafter. Since Turkey has Customs Union with the EU, she will be entailed to open up its market to the US without any reciprocal move by the American side.

Against the backdrop of contracting Middle Eastern market in a region immersed in chaos, Turkey is blocked from the Arab hinterland and is in dire need of new and secure markets with a burgeoning economy. Moreover, the U.S. and EU unilateral sanctions are hindering possible expansion of trade with Iran. Therefore, an American commitment to engage economically will be timely to secure Turkey’s stability, invigorate its Western orientation and will prove a vital link for the West with the broader neighborhood.

Thinking Turkey

The Arab Spring has revealed the limits of American power and challenged Turkey’s Middle East policy. Ankara, however, has recalibrated its regional policy and is now poised to play a regional leadership role to help influence the trajectory of politics in the new Middle East. Despite divergences in their diplomatic agendas, Turkey and the US have a vested interest in the democratic transformation of the countries like Tunisia, Libya, Egypt, Syria and
potential others as the uprisings demanding democracy, equality and freedom spread throughout the region. Washington and Ankara should deepen the bilateral relations established by President Obama and Prime Minister Erdogan in an effort to support the emergence of a more democratic Middle East. In a region where U.S.’s traditional allies in the Middle East are marginalized and democratic transformations have brought populist governments more likely to reflect the anti-Western ethos of their people than the previous authoritarian regimes, Turkey stands to be the U.S.’s only partner with enough clout to play a constructive role.

Aras is the director of Ankara's Center for Strategic Research. He is also a Public Policy fellow at the Wilson Center and head of the Center for Strategic
Research in the Ministry of Foreign Affairs, Turkey.
Yorulmazlar is a non-resident fellow at SAIS Foreign Policy Institute.

View Comments

View the original article here

Report: Jesse Jackson Jr. writing a memoir

Former Rep. Jesse Jackson Jr. (D-Ill.), who pleaded guilty last week to misusing more than $750,000 in campaign funds and faces up to five years in prison, is writing a memoir to “clear up his legacy,” according to the Chicago Tribune.

“He has nothing else to do right now,” a source told the Tribune. “He is desperately trying to change the narrative of his life story.”

Jackson will be sentenced on June 28, according to the Tribune, after spending campaign money on personal items like a Rolex watch, two stuffed elk heads, and Micheal Jackson’s fedora. Jackson’s wife, Sandi Jackson, also pleaded guilty to separate charges of filing false tax returns.

Jackson took a medical leave from Congress in the summer of 2012 for treatment for bipolar disorder, and resigned in November.

View Comments

View the original article here